Conference Coverage

Updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci; formerly known as ZL-1310; see ADC Drugmap; NCT06179069)* an antibody-drug conjugate...

The protein tyrosine kinase-7 or PTK7 is a oncofetal transmembrane pseudokinase that has emerged as a potential therapeutic target for human tumors. PTK7 is...

Preliminary results from the ongoing Phase 1 study (NCT06555744) evaluating ZW191, an antibody-drug conjugate (see ADC Drugmap) targeting folate receptor-alpha (FR⍺), were presented at...

Positive early clinical data from the NAPISTAR1-01 Phase 2/2a study (NCT06303505) investigating TUB-040, an antibody-drug conjugates (ADC) being developed by Tubulis, were presented in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress, held October 17 - 21, 2025 in Berlin, Germany.[1] (see ADC Drugmap).

Data from the dose escalation portion of the Phase 1/2 study of JK06 in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, is being presented at the European Society for Medical Oncology (ESMO) Congress, being held October 17 - 21, 2025, in Berlin, Germany.[1]

Results from the phase 2 dose optimization part of the REJOICE-Ovarian01 phase 2/3 trial (NCT06161025) showed that raludotatug deruxtecan (R-DXd, DS-6000a; see ADC Drugmap), a specifically engineered, potential first-in-class CDH6-directed antibody drug conjugate, discovered by Daiichi Sankyo and jointly developed by Daiichi Sankyo and Merck & Co (known as MSD outside of the United States and Canada), demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer.

Compelling evidence presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin, Germany, has shown that a new generation of antibody-drug conjugates (ADCs) can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

ESMO 2025: First Global Phase I Results of Izalontamab Brengitecan in Patients with Advanced Solid Tumors

At the European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, 2025 in Berlin, Germany, AbbVie will unveil new data from its...